Official reprint from UpToDate® www.uptodate.com
©2012 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2012 UpToDate, Inc.
Restless legs syndrome
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Apr 2012. | This topic last updated: Feb 9, 2012.

INTRODUCTION — Restless legs syndrome (RLS) refers to symptoms of spontaneous, continuous leg movements associated with unpleasant paresthesias [1]. These sensations occur only at rest and are relieved by movement. Sleep disturbance and a frequent association with involuntary, jerking movements of the legs during sleep, known as periodic leg movements of sleep (PLMS), are common. Nocturnal leg cramps are a separate disorder and are discussed elsewhere. (See "Nocturnal leg cramps".)

EPIDEMIOLOGY — Mild symptoms of RLS occur in 5 to 15 percent of the population; prevalence figures vary widely depending upon the population surveyed and severity of symptoms required for inclusion [2-5].

In a population study of RLS that used standard diagnostic criteria, 15,391 subjects (≥18-years-old) from the United States and five European countries (France, Germany, Italy, Spain, and the United Kingdom) completed questionnaires and the following observations were made [6]:

  • RLS symptoms of any frequency were reported by 7.2 percent.
  • RLS symptoms occurred at least twice a week and were reported as moderately or severely distressing by 2.7 percent.
  • The prevalence of RLS was approximately twice as high for women compared with men.
  • The prevalence of RLS increased with age up to age 79, and then declined.

A previous survey also found that the prevalence of restless legs (with symptoms experienced on five or more nights per month) increased with age, from 3 percent of participants ages 18 to 29, compared with 10 percent of those ages 30 to 79 and 19 percent of those ages 80 or older [7]. Increasing parity may be associated with an increased risk of RLS [8].

RLS also occurs in children. A large population-based internet survey study from the United Kingdom and United States found that the prevalence of definite RLS in children 8 to 17 years old was approximately 2 percent [9]. The presence of moderately severe or distressing RLS symptoms occurring two or more times a week was found in 0.5 percent of children ages 8 to 11 years and 1.0 percent of those 12 to 17 years old. A biologic parent with RLS symptoms was noted for >70 percent of children with RLS.

In a telephone survey of patients with RLS, 25 percent experienced their first symptoms between ages 11 and 20 [10]. Misdiagnoses such as "growing pains" and attention deficit hyperactivity disorder were common, and medical attention was often not sought until after age 40 when symptoms frequently begin to progress. In a retrospective study, 32 of 538 children and adolescent subjects (5.9 percent) presenting to a sleep disorders clinic had restless legs syndrome [11]. Low serum ferritin (<50 ng/mL [<50 mcg/L]) was found in 20 of 24 subjects (83 percent) who had ferritin levels.

A number of retrospective studies suggest that children and adults with RLS have a relatively high rate of comorbid psychiatric disorders, such as attention deficit hyperactivity disorder and mood disorders [12-15]. However, the implications of these data are unclear, since psychotropic medications may induce symptoms similar to RLS or exacerbate pre-existing RLS.

PATHOGENESIS — In most cases RLS is a primary idiopathic disorder, but it also can be associated with a variety of underlying medical disorders.

Primary RLS — The cause of primary (or idiopathic) RLS is unknown. However, a family history consistent with dominant inheritance is present in more than 40 percent of patients with idiopathic RLS [16,17]. This observation, in combination with reports of several large kindreds with RLS, suggests a genetic basis for the disorder. A genetic component is further supported by the following observations:

  • In a twin study, 10 of 12 monozygotic twin pairs were concordant for RLS, although there was considerable variance in age of onset and symptom severity [18].
  • Genetic linkage studies have identified potential susceptibility loci for RLS on chromosomes 2q [19], 9p [20,21], 12q [22,23], 14q [24], and 20p [25].
  • In a genome-wide association study (GWAS) of 401 subjects with RLS and 1644 controls, all of European descent, RLS was associated with three genetic loci: MEIS1 on chromosome 2p, BTBD9 on chromosome 6p, and a third locus between MAP2K5 and LBXCOR1 on chromosome 15q [26]. A fourth locus, PTPRD on chromosome 9p23-24, was identified in another GWAS [27], and an association of RLS with the PTPRD variant rs1975197 was confirmed in a family-based and population-based genetic study [28]. An association with BTBD9 was also found by a GWAS from Iceland in a subset of 306 subjects with RLS who had periodic limb movements of sleep [29]. (See 'Periodic limb movements of sleep' below.)
  • There is a high incidence of RLS in spinocerebellar ataxia type 3 (Machado-Joseph disease) that is unrelated to the incidence of peripheral neuropathy in that disorder [30].

Several neurophysiologic changes have been identified in patients with RLS, including reduced motor cortex inhibition, spinal flexor reflex hyperactivity, and brainstem reflex abnormalities, but these are nonspecific findings, the significance of which is currently undetermined [31].

It has been assumed that RLS is a peripheral disorder, but studies of brain dopamine metabolism raise the possibility of a central nervous system cause. One hypothesis holds that RLS arises from dysfunction of hypothalamic dopaminergic cells that are the source of spinal cord dopamine [32]. Data from functional imaging with single photon emission computed tomography (SPECT) and positron emission tomography (PET) are conflicting, having demonstrated reduced [33,34], increased [35], or unchanged [36] basal ganglia dopamine receptor binding and 18F-Dopa uptake in patients with RLS compared with control subjects. This is of particular interest since there is probably an increased incidence of RLS in Parkinson disease [37].

Brain iron metabolism may also play a role. (See 'Iron deficiency' below.)

Hypocretins are hypothalamic neuropeptide transmitters that participate in the normal control of the sleep wake cycle and are depleted in the pathophysiology of narcolepsy. (See "Diagnosis and neurobiology of narcolepsy", section on 'Genetic factors'.)

Hypocretins increase arousal and interact with the dopamine system [38]. A small clinical study also found that increases in hypocretin levels in the cerebrospinal fluid were associated with an increased incidence of restless legs syndrome, particularly early onset disease [39].

Secondary RLS — RLS can occur secondary to a number of disorders including iron deficiency, uremia, diabetes mellitus, rheumatic disease, and venous insufficiency, among others.

Iron deficiency — Iron deficiency has been considered a possible cause of RLS since the original publications on this disorder [40]. Subsequently, the relationship between iron status and RLS has been examined in several studies [41-44]:

  • In a report of 18 elderly patients with RLS and 18 matched controls, the serum ferritin concentration was significantly lower in patients with RLS (33 versus 59 ng/mL [33 versus 59 mcg/L]) and was inversely correlated with the severity of symptoms [41]. Although the hemoglobin concentration in patients and controls was similar, treatment with ferrous sulfate for two months reduced RLS symptoms in 14 of 15 patients.
  • In a second study, patients with RLS had a lower spinal fluid ferritin concentration than age-matched controls (1.11 versus 3.50 ng/mL) and a higher spinal fluid transferrin concentration (26.4 versus 6.71 ng/mL) [42]. However, there was no difference in serum ferritin and transferrin between the two groups.
  • A study that performed MRI estimates of brain iron concentration in a small number of patients with RLS found significantly reduced iron in the substantia nigra [43]. Compared with controls, another study found evidence that the iron management protein profile at the site of blood-brain interface was altered in patients with RLS, with a decrease in transferrin receptor expression in the microvasculature in the setting of relative brain iron [45].
  • Neuropathological studies found altered iron management protein levels that were consistent with iron insufficiency in substantia nigra neuromelanin cells from patients with RLS [46,47]. Quantitative analyses showed decreased levels of ferritin, divalent metal transporter 1 (DMT1), ferroportin, transferrin receptor, and iron regulatory protein 1 (IRP1) compared with controls [47].

While these findings are not conclusive, they warrant the measurement of serum ferritin levels in patients with RLS and a trial of oral iron therapy when ferritin levels are low. (See "Causes and diagnosis of anemia due to iron deficiency" and "Treatment of anemia due to iron deficiency", section on 'Oral iron therapy'.)

Oral iron therapy may also be considered when ferritin levels are within normal range, as some patients without iron deficiency may still respond.

End-stage renal disease — RLS is common among dialysis patients, with a reported incidence of 6 to 60 percent [48-50]. (See "Uremic polyneuropathy".) Anemia may play a role in these circumstances, since low-dose erythropoietin therapy significantly reduced RLS in one report [51]. In addition, iron therapy among dialysis patients with functional, but not absolute, iron deficiency was beneficial in another study [52]. (See "Uremic polyneuropathy", section on 'Restless legs syndrome'.)

A third study, however, found that a low serum parathyroid hormone concentration, but not serum hemoglobin, was associated with the presence of RLS in 136 dialysis patients [53].

Diabetes mellitus — RLS can be a prominent feature of diabetic neuropathy [54,55], and type 2 diabetes may be an independent risk factor for RLS development [56]. RLS and other sensory symptoms of neuropathy often improve following successful pancreatic-kidney transplantation [57].

Multiple sclerosis — Mounting evidence suggests that RLS is associated with multiple sclerosis (MS) [58-60], but data are conflicting [61]. In the largest study, a prospective multicenter epidemiologic survey of 861 patients with MS and 649 control subjects, the prevalence of RLS was significantly higher in patients with MS than in controls (19 versus 4 percent, relative risk 5.4, 95% CI 3.56-8.26) [59].

Parkinson disease — Both RLS and Parkinson disease appear to involve disturbances in the dopaminergic neurotransmitter system, suggesting a common mechanism [62]. However, few studies have examined the relationship between these two disorders, and progress is hampered by a lack of understanding regarding the pathophysiology of RLS. In contrast to Parkinson disease, preliminary neuropathologic evidence suggests that the pathogenesis of RLS does not involve neuronal degeneration of nigrostriatal pathways [62].

Estimates of the prevalence of RLS among patients with Parkinson disease vary widely from 0 to 21 percent; some [37,63-65] but not all [66-68] studies have found that the prevalence of RLS is higher in patients with Parkinson disease than in the general population. Probably the best data come from a population-based study from Norway of 200 patients with early untreated Parkinson disease who were compared with 173 matched control subjects [68]. The frequency of RLS was nonsignificantly higher in patients with Parkinson disease compared with controls (12.5 versus 9.6 percent, relative risk [RR] 1.76, 95% CI 0.9-3.43). This finding suggests that the overlap of RLS with untreated Parkinson disease is most likely coincidental [69]. However, the issue is not settled. One series found that patients with both Parkinson disease and RLS were older at RLS onset, were less likely to have a family history of RLS, and had lower serum ferritin levels compared with patients with idiopathic RLS [37]. When both disorders were present, Parkinson disease preceded RLS in 68 percent of patients. There are also indications that long-term antiparkinson therapy may contribute to the apparent increased prevalence of RLS in patients with Parkinson disease [64]. One potential explanation is that wearing-off episodes related to levodopa therapy can be associated with symptoms that mimic RLS, such as unpleasant sensations and the urge to move the legs [70]. Another is that prolonged levodopa exposure can induce augmentation of RLS, characterized by increasingly severe symptoms, onset earlier in the day or spread to other body parts [71].

Akathisia, a subjective feeling of motor restlessness accompanied by inability to sit or stand still, is also common in Parkinson disease, with prevalence rates ranging from 26 to 45 percent [66,72] and the potential for overlap with RLS (see 'Diagnosis' below) [73]. Due to the similarity of symptoms, some patients with akathisia may be misidentified as having RLS, but the two can be distinguished. As an example, leg motor restlessness, defined as the urge to move the legs in subjects not fulfilling RLS criteria, was an outcome measure in the population-based case-control study cited above [68]. The frequency of leg motor restlessness was significantly higher in patients with Parkinson disease compared with controls (25 versus 8.7 percent, RR 2.84, 95% CI 1.43-5.61) [68]. However, the significance of this finding is uncertain, since wearing-off episodes or other effects of antiparkinson medications may contribute to motor restlessness in patients with Parkinson disease.

Pregnancy — Pregnancy appears to be a risk factor for the occurrence or worsening of RLS [74-77]. In a study of 626 pregnant women admitted to a single center, the diagnosis of RLS was determined by the four International RLS Study group criteria (see 'Diagnosis' below); the prevalence of RLS in this group of women was 10 percent before pregnancy and increased to 27 percent during pregnancy [77]. The highest rates were seen in the third trimester and dropped quickly after delivery. Older studies have reported lower rates of RLS during pregnancy [74-76], but none of them had used or strictly applied the four standard diagnostic criteria.

The cause of the increased frequency of RLS during pregnancy is unclear, but possible causes include iron deficiency, folate deficiency, and hormonal changes [77,78].

Treatment recommendations for RLS in pregnancy are summarized below (see 'Treatment in pregnancy' below).

Rheumatic disease — The relationship between RLS and rheumatic disease is unclear.

  • In one study, RLS was present in 25 percent of patients with rheumatoid arthritis compared with 4 percent of controls with osteoarthritis or seronegative arthropathy and was associated with greater disease activity and severity [79].
  • A higher than expected prevalence of RLS has been reported in patients with Sjögren's syndrome [80] and in systemic lupus erythematosus [81].
  • In a study of 135 patients with fibromyalgia, 42 had RLS [82].
  • A report from a neurology specialty clinic found no evidence of clinical rheumatologic disease among 68 patients with RLS, and only four patients had positive serologies for rheumatic diseases [83].

Venous insufficiency — Varicose veins have been associated with RLS and treatment of varicose veins and chronic venous insufficiency may be helpful in some patients. As an example, one study found that 312 of 1397 patients seeking treatment for varicose veins had symptoms of RLS on a screening questionnaire and interview [84]. Sclerotherapy was performed in 113 of the patients with RLS; 98 percent reported initial relief of RLS. Symptom relief was maintained in 72 percent at two years of follow-up.

Treatment of chronic venous insufficiency with hydroxyethylrutoside also appears to be beneficial in patients with RLS but not as striking or dramatic as sclerotherapy. (See "Medical management of lower extremity chronic venous disease".) A meta-analysis of 15 trials that included a total of 1973 patients found that RLS improved in 36 percent of those treated with an average dose of 1000 mg/day for a minimum of four weeks compared with 26 percent of placebo controls [85].

Other miscellaneous conditions — Other disorders that have been reported to be associated with RLS include other peripheral neuropathies, amyotrophic lateral sclerosis, vitamin deficiencies, lumbosacral radiculopathy, spinal stenosis, excess caffeine intake, administration of mianserin, hypoglycemia, hypothyroidism, and obesity [16,86-93].

CLINICAL MANIFESTATIONS — Although the subjective symptoms of RLS are often difficult to describe, the clinical features are highly stereotyped. The hallmark of RLS is a marked discomfort in the legs that occurs only at rest and is immediately relieved by movement. The abnormal feelings are typically deep seated and localized below the knees. Distribution is usually bilateral, but some asymmetry may occur and the arms can be affected in more severe cases.

Terms that patients use to describe the symptoms include crawling, creeping, pulling, itching, drawing, or stretching, all localized to deep structures rather than the skin. Pain and tingling paresthesia of the type that occurs in painful peripheral neuropathy are usually absent, and there is no sensitivity to touching of the skin.

Symptoms typically worsen towards the end of the day and are maximal at night, when they appear within 15 to 30 minutes of reclining in bed. In severe cases symptoms may occur earlier in the day while the patient is seated, thereby interfering with attending meetings, sitting in a movie theater, and similar activities. In milder cases patients will fidget, move in bed, and kick or massage their legs for relief. Patients with more severe symptoms feel forced to get out of bed and pace the floor to relieve symptoms.

Periodic limb movements of sleep — Periodic limb movements of sleep (PLMS) are sudden jerking leg movements that commonly accompany RLS. These are repetitive, highly stereotyped movements that typically involve extension of the big toe with partial flexion of the ankle, knee, and sometimes the hip. The patient is usually unaware of these movements. The prevalence of PLMS increases with age, and PLMS are identified in the vast majority of patients with RLS during sleep laboratory evaluations.

Treatment is not necessary if PLMS occur without sleep complaints.

In some patients, however, the periodic limb movements may cause partial or total arousal from sleep and provide an additional cause of insomnia and excessive daytime drowsiness. In such cases, periodic limb movement disorder (PLMD) of sleep is the term used to characterize the association of PLMS and hypersomnolence. A case-control polysomnography study found that 45 patients with RLS had significantly higher indices of sleep fragmentation and of PLMS than 45 matched controls [94].

Although data are limited, treatment of symptomatic PLMD is approached using the same drugs and regimens as are used to treat RLS, particularly when PLMD is accompanied by RLS [95,96]. Benzodiazepines, pramipexole, and ropinirole are often used to treat PLMD in the absence of RLS. (See 'Treatment' below and 'Benzodiazepines' below.)

Formal diagnostic criteria for PLMD require polysomnography as follows [97]:

  • There is clinical evidence of disturbed sleep or daytime fatigue
  • Polysomnography demonstrates repetitive movements that are 0.5 to 5 seconds in duration, typically separated by an interval of 20 to 40 seconds (range 5 to 90 seconds)
  • There are more than 15 periodic limb movements per hour of sleep time in most adults and more than five per hour of sleep in children
  • The periodic limb movements are not better explained by another disorder

DIAGNOSIS — The diagnosis of RLS is often delayed or missed, especially when the symptoms are relatively mild or non-specific. The diagnosis of primary RLS rests on typical symptoms in the presence of a normal neurologic examination. Patients with secondary forms of RLS due to peripheral neuropathy may have related sensory and reflex abnormalities.

The International Restless Legs Study Group proposed the following four features as essential criteria for the diagnosis of RLS [98]:

  • An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. Sometimes the urge to move is present without the uncomfortable sensations, and sometimes the arms or other body parts are involved in addition to the legs.
  • The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
  • The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
  • The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. When symptoms are severe, the worsening at night may not be noticeable but must have been previously present.

Supportive criteria for the diagnosis of RLS include the following [98]:

  • A family history of RLS
  • A positive response to dopaminergic drugs
  • Periodic limb movements during wakefulness or sleep as assessed with polysomnography or leg activity devices

Polysomnography in a sleep laboratory is not necessary for the diagnosis, but it may be helpful, especially when RLS is resistant to treatment [99]. (See 'Periodic limb movements of sleep' above.)

The differential diagnosis begins with separating primary from secondary RLS. Iron deficiency and renal failure are particularly important to exclude; a normal hemoglobin does not rule out iron deficiency if the serum ferritin is low. Peripheral neuropathy, lumbosacral radiculopathy, and ordinary leg cramps, all of which are typically more painful conditions, should also be considered. (See "Nocturnal leg cramps".)

RLS should be differentiated from akathisia, a common side effect of the phenothiazine antipsychotic drugs and selective serotonin reuptake inhibitor (SSRI) antidepressants. Akathisia (from the Greek "not to sit") is a more constant and generalized feeling of motor restlessness unassociated with subjective discomfort localizing to the legs. In contrast to akathisia, RLS has a circadian rhythm (worse at night when the patient is sitting or in bed) and is commonly accompanied by paresthesias and myoclonic jerks during the waking state [100]. The syndrome of "painful legs and moving toes" is a rare disorder of unknown cause characterized by more prominent involuntary toe movements and leg pain [101].

TREATMENT — A number of treatments for RLS have been studied in primarily small, randomized, controlled trials. Placebo controlled studies are particularly important since RLS is normally characterized by fluctuations and remissions.

Iron replacement therapy is suggested for all patients with RLS. Nonpharmacologic measures such as mental alerting activities, avoidance of aggravating factors, and stretching exercises for the posterior leg muscles (picture 1) may be helpful for some patients with RLS [102].

Pharmacotherapy for idiopathic RLS with benzodiazepines, dopaminergic drugs, or, in resistant cases, opioids have been successful in many patients [103]. Dopaminergic drugs such as levodopa (L-dopa) and dopamine agonists appear to be more effective than benzodiazepines in patients with RLS, although there are no direct comparison studies. (See 'Levodopa' below and 'Pramipexole and ropinirole' below.)

Expert panel recommendations — An algorithm for the management of RLS devised by an expert panel was published in 2004 and highlights three particular types of RLS (intermittent, daily, and refractory) [102]. Recommendations for these three types are excerpted here.

Intermittent RLS — Intermittent RLS is defined as RLS that is troublesome enough when present to require treatment but that is not sufficiently frequent to require regular daily medication use [102]. Treatment options include:

Daily RLS — Daily RLS is defined as RLS that is frequent and troublesome enough to require daily treatment [102]. Treatment options include:

Refractory RLS — Refractory RLS is defined as daily RLS treated with a dopamine agonist but with a poor response [102]. The response is considered poor if there is an inadequate initial response despite adequate doses of medication or if the response becomes inadequate with time despite increasing doses. Augmentation (the onset of symptoms earlier in the day or extension of symptoms to arms or trunk) that is not controllable with additional earlier doses of the drug also qualifies RLS as refractory, as does intolerable adverse effects.

Referral to a specialist for RLS management should be considered for these patients [102]. Four different pharmacologic treatment approaches are recommended:

  • Change to gabapentin
  • Change to a different dopamine agonist
  • Add a second agent such as gabapentin, a benzodiazepine, or an opioid
  • Change to a high potency opioid or tramadol

Nonpharmacologic therapy — Nonpharmacologic therapy is recommended by the expert panel for patients with intermittent or daily RLS [102]. The therapy involves the following components:

  • Iron replacement therapy
  • Mental alerting activities
  • Avoidance of aggravating factors
  • Short daily hemodialysis for patients in renal failure

Online information and support is available for patients with RLS through The Restless Legs Syndrome Foundation.

Iron replacement — A trial of oral iron therapy is suggested for all patients with RLS, particularly premenopausal women, as some patients without evidence of iron deficiency may still respond favorably. Iron replacement is indicated if the serum ferritin level is lower than 45 to 50 ng/mL (45 to 50 mcg/L).

The suggested regimen is ferrous sulfate (325 mg three times a day) in combination with vitamin C (100 to 200 mg) with each dose of ferrous sulfate to enhance absorption. (See "Treatment of anemia due to iron deficiency", section on 'Oral iron therapy'.)

Ferritin levels should be checked after three to four months of therapy and then every three to six months until the serum ferritin level is >50 ng/mL (>50 mcg/L) and iron saturation is greater than 20 percent.

Avoidance of aggravating drugs — Caffeine, nicotine, and alcohol may aggravate RLS symptoms. A trial of abstinence is reasonable in many patients.

Antidepressants, neuroleptic agents, dopamine-blocking antiemetics such as metoclopramide, or sedating antihistamines (including those found in nonprescription medications) may contribute to RLS symptoms. However, discontinuation may not be possible without causing patient harm. If antidepressants are necessary, the symptoms of secondary RLS can usually be treated in the same way as primary RLS. Bupropion is an alternative antidepressant that may be less likely to induce or worsen RLS [104].

Short daily hemodialysis for patients in renal failure — In a prospective cohort study (FREEDOM study) that included 94 patients with disturbed sleep and/or restless leg syndrome, short daily hemodialysis resulted in a sustained improvement in restless legs symptoms as assessed by the International Restless Leg Syndrome Study Group rating scale [105]. However the percentage of patients prescribed medication for restless leg syndrome did not decrease. (See "Short daily hemodialysis", section on 'Quality of life'.)

Dopamine agonists — Dopamine agonists belong to a class of drugs that directly stimulate dopamine receptors and have a longer half-life (four to six hours) than levodopa (90 minutes). They are generally superior to levodopa for the treatment of daily RLS. In a 2011 meta-analysis of 38 trials evaluating dopamine agonists for the treatment of RLS that included cabergoline, lisuride, pergolide, pramipexole, ropinirole, rotigotine, and sumanirole, all except sumanirole were superior to placebo [106]. In two trials, cabergoline and pramipexole were superior to levodopa for improvement in disease severity as measured by the International Restless Leg Syndrome Study Group rating scale (IRLS).

Pramipexole and ropinirole — The non-ergot dopamine agonists, pramipexole and ropinirole, are less likely to cause side effects than other dopamine agonists. These agents are considered to be the drugs of choice in most patients with daily RLS [102]. They may also be helpful in patients with intermittent RLS.

  • The benefit of ropinirole for RLS was demonstrated in three similar randomized controlled trials [107-109]. As an example, one of these trials enrolled 284 patients with moderate to severe RLS; improvement on the primary outcome measure of symptoms as assessed by the International Restless Legs Syndrome Study Group rating scale (IRLS) was significantly greater for ropinirole treatment (average dose 1.13 mg/day) than for placebo [107].
  • The benefit of pramipexole was demonstrated in a 12-week double-blind trial that assigned 344 patients with moderate or severe RLS to one of three pramipexole regimens (0.25, 0.50, and 0.75 mg/daily) or to placebo [110]. The initial pramipexole dose was 0.125 mg/daily for the first week, and the dose was titrated up to the assigned dose over the first three weeks of the trial. All three doses of pramipexole were superior to placebo on the two primary outcome measures (patient-rated symptom severity improvement measured by the IRLS, and clinician-rated improvement). Pramipexole was well tolerated; nausea and somnolence were the most frequent side effects associated with its use.

Adverse effects with pramipexole and ropinirole are usually mild, transient, and limited to nausea, lightheadedness, and fatigue; these usually resolve within 10 to 14 days. Less frequent side effects include nasal stuffiness, constipation, insomnia, and leg edema; these are reversible if the medication is stopped. Sudden, unexpected sleep attacks, as described in patients with Parkinson disease on higher doses of pramipexole, do not appear to occur in patients on low-dose pramipexole (mean of 0.37 mg/day) for RLS [111].

As first reported in patients with Parkinson disease, dopamine agonist therapy in patients with RLS may be associated with an increased risk of impulse control disorders such as pathologic gambling, compulsive eating and shopping, and inappropriate hypersexuality [112]. (See "Pharmacologic treatment of Parkinson disease", section on 'Impulse control disorders'.)

The onset of action for dopamine agonists is typically 90 to 120 minutes after intake. Therefore, these medications should be started two hours before RLS symptoms start [102]. The recommended starting doses are [102]:

  • Pramipexole 0.125 mg once daily. The dose may be increased by 0.125 mg every two to three days until relief is obtained. In a clinical trial, all three doses of pramipexole (0.25, 0.50, and 0.75 mg/daily) were equally effective, and some patients responded to the initial dose of 0.125 mg daily [110]. However, side effects were more common with the 0.50 mg and 0.75 mg daily. Therefore, it is expected that 0.25 mg daily has the best therapeutic margin. Most patients require 0.5 mg or less, but doses up to 2 mg may be needed.
  • Ropinirole 0.25 mg once daily. The dose may be increased by 0.25 mg every two to three days until relief is obtained. Most patients require 2 mg or less, but doses up to 4 mg or higher may be needed.

Augmentation is less common with these drugs than with levodopa, but it has been reported in up to one-third of patients taking pramipexole for two years [113,114]. The risk of augmentation with ropinirole is unknown [102]. In one study, augmentation was significantly more common in patients with a family history of restless legs syndrome and in those who had no evidence of neuropathy on electromyography or nerve conduction studies [115].

Unlike levodopa, additional doses of a dopamine agonist earlier in the day can often reduce the risk and intensity of augmentation [102]. The development of augmentation with one dopamine agonist does not necessarily predict augmentation with a different agonist [113]. In addition, ropinirole and pramipexole can be substituted for one another. However, therapy should be changed to a different class of medications if augmentation develops with a second dopamine agonist [102].

Other dopamine agonists — Other dopamine agonists are also effective in RLS but are used infrequently.

  • Cabergoline (0.5 to 4 mg as an evening dose) is a dopamine agonist with a long half-life (65 hours) that may benefit patients who experience rebound symptoms with shorter half-life medications [86,116,117].

  • In a five-week randomized clinical trial of 85 patients with RLS, cabergoline at doses of 0.5, 1.0, and 2.0 mg/day (taken at least three hours before bedtime) was effective compared with placebo in treating RLS symptoms and sleep disturbance [118]. In an open-label, one-year extension, a mean daily dose of cabergoline 2.2 mg/day was required to maintain improvement of RLS symptoms [118].
  • A later five-week randomized controlled trial of 40 patients with moderate to severe RLS found that cabergoline 2 mg once daily in the evening was significantly more effective than placebo by polysomnography for reducing PLMS-related arousal [119].
  • Side effects in the first trial including nausea, constipation, headache, dizziness, fatigue, and drowsiness caused treatment discontinuation in 11 patients (13 percent) [118]. Augmentation (the onset of symptoms earlier in the day or extension of symptoms to arms or trunk) was observed in six treated patients (9 percent) in the long-term phase. In a study of patients with Parkinson disease, high cumulative dose and long-term treatment with cabergoline was associated with an increased risk of cardiac valvulopathy [120].

  • Pergolide was effective for relieving symptoms of RLS [106]. However, pergolide was associated with restrictive cardiac valve disease in 33 percent of patients when used in high doses to treat PD [121]. Because of this association, pergolide was voluntarily withdrawn from the United States market in 2007 [122].

Levodopa — The efficacy of levodopa (levodopa) for restless legs syndrome has been demonstrated in small randomized trials and a meta-analysis [123]. The following trials illustrate the range of findings:

  • In one double-blind, crossover study lasting four weeks, an evening dose of levodopa 200 mg with benserazide (a peripheral dopa decarboxylase inhibitor used in Europe and equivalent to carbidopa used in the United States) significantly reduced the frequency of awakenings and duration of waking periods in 13 patients with RLS compared with placebo [124].
  • In a second double-blind trial in which 20 patients with RLS were given levodopa, 50 to 200 mg daily with benserazide or lactose on alternate days for an unspecified period of time, 17 patients reported complete relief with levodopa [125].
  • Levodopa was also effective in a double-blind study of uremic RLS [126].

Tachyphylaxis (a decreasing response with continual treatment) to levodopa has been reported [127], but in one long-term study lasting two years, 26 of 30 patients initially responding to levodopa maintained a good response [128].

Three different problems may occur with patients on levodopa therapy:

  • Augmentation is a worsening of RLS symptoms earlier in the day after an evening dose of medication, including earlier onset of symptoms, increased intensity of symptoms, or spread of symptoms to the arms [129]. It occurs in up to 70 percent of patients taking daily levodopa [130].
  • Rebound is the recurrence of RLS early in the morning. It occurs in 20 to 35 percent of patients taking levodopa [127,130].
  • Recurrence of symptoms in the second half of the night may occur.

An expert advisory panel on RLS recommends levodopa only for intermittent RLS [102]. The risk of augmentation may be decreased with intermittent use of dopaminergic drugs, although this has not been well studied. The expert panel recommends discontinuation of the drug if augmentation occurs [102]. Controlled release levodopa (CR) combined with standard levodopa may help sleep quality during the second half of the night for patients who experience recurrence [131].

For best absorption, levodopa should not be taken with high protein foods. Suggested agents include:

  • Carbidopa-levodopa 25 mg/100 mg, one-half or one tablet, can be used for intermittent RLS that occurs during the evening, at bedtime, or on waking during the night. Additionally, this medication may be helpful for RLS associated with specific triggers including lengthy travel by auto or airline, or spectator events with prolonged sitting.
  • Controlled release (CR) carbidopa-levodopa, 25 mg/100 mg before bed may be helpful for RLS that awakens the patient during the night.

Benzodiazepines — Benzodiazepines are useful in mild cases of RLS, particularly in younger patients [132,133]. Diazepam has been used in RLS for many years, although there have been no controlled trials. In a small randomized, double-blind, crossover trial, treatment with clonazepam, 1.0 mg daily, was superior to placebo in six patients with RLS [134]. In an open trial, 14 of 15 patients with RLS due to uremia responded to clonazepam, 1 to 2 mg daily [135].

An RLS expert panel algorithm recommends benzodiazepines or benzodiazepine agonists for intermittent RLS, especially if the patient has another cause of poor sleep in addition to RLS [102]. Short-acting agents can be helpful for sleep onset insomnia caused by RLS; these agents include:

For RLS that awakens the patient later in the night, the expert panel recommends intermediate acting agents such as temazepam 15 to 30 mg [102].

Although most trials have been performed with clonazepam, its long duration of action may result in more adverse effects, such as nocturnal unsteadiness and drowsiness or cognitive impairment in the morning [102]. However, at least one study has shown a low rate of adverse effects from clonazepam in elderly patients [132].

Long-term maintenance treatment with benzodiazepines is limited by tolerance in many patients, but abuse appears to be low in this disorder.

Gabapentin — Gabapentin and the extended release formulation of gabapentin enacarbil are alternative choices for patients with daily RLS [102,136,137]. Gabapentin, mean dose 733 mg/day, was effective in a four-week open-label study of nine patients with idiopathic RLS [138], and at a much higher mean dose (1,855 mg) in a randomized, placebo-controlled trial of 22 patients [139]. Among dialysis patients, gabapentin (200 to 300 mg three times weekly after hemodialysis) was effective in a 12-week, double-blind crossover study [140].

Although the trial data above suggest that mean doses of 1800 mg a day are needed, many patients appear to benefit from a lower dose. The expert panel suggests beginning treatment with 100 to 300 mg per dose because of the tendency of the drug to cause somnolence and gait unsteadiness [102].

Gabapentin may be particularly useful in patients whose symptoms are less intense and in patients in whom RLS is perceived as painful. It may also be useful when RLS occurs in the setting of a painful peripheral neuropathy or an unrelated chronic pain syndrome. Gabapentin may also be considered in the treatment of RLS in association with neurodegenerative disorders, such as PD or dementia.

Opioids — A variety of opioids, including codeine and methadone, have been reported to be helpful for RLS in uncontrolled trials [141]. In a double-blind, four week crossover study of 11 patients, oxycodone at a mean dose 15.9 mg/day, was superior to placebo with regard to number of sleep arousals, PLMS frequency, and sleep efficiency [142]. One long-term retrospective study of 113 patients treated with opioids has shown persistent benefit, but a small number of patients developed sleep apnea [143].

Similar to benzodiazepines, opioid abuse potential is low in patients with RLS. Nevertheless, we typically restrict use to patients with more severe symptoms who fail to respond to benzodiazepines or dopaminergic drugs.

The expert RLS panel recommends more liberal use of low potency opioids or opioid agonists for intermittent RLS and as an alternative for daily RLS [102]. These drugs are usually taken before bed and include:

For patients with refractory RLS, the same panel recommends change to a high potency opioid or tramadol as one of four different management approaches (see 'Refractory RLS' above) [102]. High potency opioids may be effective in the management of RLS, and escalation of doses and dependence are uncommon in the absence of a history of substance abuse. High potency opioids may be used one to three times a day depending on timing of symptoms; agents include [102]:

Other drugs — Pregabalin (starting dose 150 mg/daily, mean dose 337 mg/daily) was superior to placebo for improving symptoms of RLS in a 12-week randomized controlled trial of 58 patients [144]. Other drugs that may be useful in RLS but have been reported in only a small number of mainly open studies include carbamazepine (mean dose 236 mg/day) [145], clonidine (0.05 mg/day) [146], propranolol (40 to 120 mg/day) [147], and amantadine (up to 300 mg/day) [148].

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)

RECOMMENDATIONS — Recommendations for RLS treatment by the expert panel are listed above (see 'Expert panel recommendations' above). We recommend the following sequence of pharmacologic therapy in patients with RLS:

  • A trial of oral iron therapy is suggested for all patients with RLS, particularly premenopausal women, as some patients without evidence of iron deficiency may still respond favorably.
  • Begin pharmacologic treatment with pramipexole (0.125 mg) or ropinirole (0.25 mg) approximately one hour before the usual time of symptom onset; the dose is titrated upward according to response. These drugs are effective and well tolerated by most patients. Pramipexole doses above 0.75 mg/day and ropinirole doses above 4 mg/day are of unproven benefit. (See 'Pramipexole and ropinirole' above.)
  • An alternative is levodopa/carbidopa, 25/100 mg given before symptom onset in patients unable to tolerate a dopamine agonist. In some cases a controlled release formulation of levodopa may be necessary to get the patient through the night or to avoid rebound daytime symptoms. (See 'Levodopa' above.)
  • Clonazepam, 0.5 mg before sleep can be used alone or as adjunctive treatment.
  • Gabapentin may be a good additional option because of its relative lack of adverse and sedative effects.
  • Opioids should be reserved as a final option, either alone or in conjunction with other medications.

Combination therapy is often useful, and periodic changes in choice of medication to deal with tolerance are frequently necessary. In some patients, additional doses of medication may be necessary during the day to manage diurnal symptoms.

Cost of medications — The treatment plan should include consideration of prescription costs. Typical monthly costs will be highest for cabergoline; intermediate for pramipexole, ropinirole, and gabapentin; lower for levodopa/carbidopa; and lowest for carbamazepine.

Treatment in pregnancy — The treatment of RLS in pregnant women is complicated by the fact that nearly all of the drugs used for RLS are considered pregnancy risk factor C or D (table 1). The one major exception is pergolide, which has other serious side effects (see 'Other dopamine agonists' above). The following options are therefore suggested:

  • Opioids (see 'Opioids' above) can be used in the second or third trimester if treatment of RLS symptoms is necessary. The lowest effective dose of opioids should be used for the shortest period of time to reduce the risk of neonatal withdrawal. In most patients, RLS begins in the third trimester of pregnancy and disappears toward the end of the pregnancy (see 'Pregnancy' above).
  • Oral iron supplements should be maintained since it appears that women with RLS in pregnancy have lower hemoglobin and mean corpuscular volume than healthy subjects (see 'Pregnancy' above). In exceptional cases, parenteral iron therapy is a consideration (see 'Iron replacement' above).
  • Nonpharmacologic therapy (see 'Nonpharmacologic therapy' above) should be tried if RLS symptoms occur earlier than the third trimester. Leg stretching before sleep (picture 1) and use of elastic stockings may also be helpful. Elastic stockings or sclerotherapy should be considered if varicose veins are prominent.
  • The patient should be counseled regarding the benign nature of the problem.

Most drugs for RLS are not recommended or are not rated by the American Academy of Pediatrics for use during breast feeding. Codeine is considered compatible with breast feeding but should be used with caution.

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. O'Keeffe ST. Restless legs syndrome. A review. Arch Intern Med 1996; 156:243.
  2. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994; 17:739.
  3. Nichols DA, Allen RP, Grauke JH, et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med 2003; 163:2323.
  4. Högl B, Kiechl S, Willeit J, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005; 64:1920.
  5. Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011; 26:114.
  6. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165:1286.
  7. Phillips B, Young T, Finn L, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160:2137.
  8. Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004; 164:196.
  9. Picchietti D, Allen RP, Walters AS, et al. Restless legs syndrome: prevalence and impact in children and adolescents--the Peds REST study. Pediatrics 2007; 120:253.
  10. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 1996; 46:92.
  11. Kotagal S, Silber MH. Childhood-onset restless legs syndrome. Ann Neurol 2004; 56:803.
  12. Pullen SJ, Wall CA, Angstman ER, et al. Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study. J Clin Sleep Med 2011; 7:587.
  13. Lee HB, Hening WA, Allen RP, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008; 20:101.
  14. Winkelmann J, Prager M, Lieb R, et al. "Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol 2005; 252:67.
  15. Hornyak M. Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management. CNS Drugs 2010; 24:89.
  16. Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999; 22:970.
  17. Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12:61.
  18. Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000; 55:1404.
  19. Pichler I, Marroni F, Volpato CB, et al. Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet 2006; 79:716.
  20. Chen S, Ondo WG, Rao S, et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 2004; 74:876.
  21. Lohmann-Hedrich K, Neumann A, Kleensang A, et al. Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? Neurology 2008; 70:686.
  22. Desautels A, Turecki G, Montplaisir J, et al. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001; 69:1266.
  23. Desautels A, Turecki G, Montplaisir J, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 2005; 62:591.
  24. Bonati MT, Ferini-Strambi L, Aridon P, et al. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003; 126:1485.
  25. Levchenko A, Provost S, Montplaisir JY, et al. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology 2006; 67:900.
  26. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007; 39:1000.
  27. Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008; 40:946.
  28. Yang Q, Li L, Yang R, et al. Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome. Mov Disord 2011; 26:516.
  29. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357:639.
  30. Schöls L, Haan J, Riess O, et al. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology 1998; 51:1603.
  31. Chokroverty S, Jankovic J. Restless legs syndrome: a disease in search of identity. Neurology 1999; 52:907.
  32. Clemens S, Rye D, Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006; 67:125.
  33. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54:502.
  34. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999; 52:932.
  35. Cervenka S, Pålhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006; 129:2017.
  36. Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57:1307.
  37. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002; 59:421.
  38. Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002; 25:283.
  39. Allen RP, Mignot E, Ripley B, et al. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 2002; 59:639.
  40. EKBOM KA. Restless legs syndrome. Neurology 1960; 10:868.
  41. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994; 23:200.
  42. Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000; 54:1698.
  43. Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001; 56:263.
  44. Silber MH, Richardson JW. Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clin Proc 2003; 78:52.
  45. Connor JR, Ponnuru P, Wang XS, et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011; 134:959.
  46. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003; 61:304.
  47. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004; 62:1563.
  48. Walker S, Fine A, Kryger MH. Sleep complaints are common in a dialysis unit. Am J Kidney Dis 1995; 26:751.
  49. Thorp ML. Restless legs syndrome. Int J Artif Organs 2001; 24:755.
  50. Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004; 43:763.
  51. Harris DC, Chapman JR, Stewart JH, et al. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med 1991; 21:693.
  52. Sloand JA, Shelly MA, Feigin A, et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004; 43:663.
  53. Collado-Seidel V, Kohnen R, Samtleben W, et al. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998; 31:324.
  54. O'Hare JA, Abuaisha F, Geoghegan M. Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir J Med Sci 1994; 163:132.
  55. Lopes LA, Lins Cde M, Adeodato VG, et al. Restless legs syndrome and quality of sleep in type 2 diabetes. Diabetes Care 2005; 28:2633.
  56. Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep 2007; 30:866.
  57. Müller-Felber W, Landgraf R, Wagner S, et al. Follow-up study of sensory-motor polyneuropathy in type 1 (insulin-dependent) diabetic subjects after simultaneous pancreas and kidney transplantation and after graft rejection. Diabetologia 1991; 34 Suppl 1:S113.
  58. Auger C, Montplaisir J, Duquette P. Increased frequency of restless legs syndrome in a French-Canadian population with multiple sclerosis. Neurology 2005; 65:1652.
  59. Italian REMS Study Group, Manconi M, Ferini-Strambi L, et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep 2008; 31:944.
  60. Deriu M, Cossu G, Molari A, et al. Restless legs syndrome in multiple sclerosis: a case-control study. Mov Disord 2009; 24:697.
  61. Gómez-Choco MJ, Iranzo A, Blanco Y, et al. Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis. Mult Scler 2007; 13:805.
  62. Garcia-Borreguero D, Odin P, Serrano C. Restless legs syndrome and PD: a review of the evidence for a possible association. Neurology 2003; 61:S49.
  63. Krishnan PR, Bhatia M, Behari M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord 2003; 18:181.
  64. Lee JE, Shin HW, Kim KS, Sohn YH. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord 2009; 24:579.
  65. Guerreiro TM, Nishikawa DR, Ferreira LC, et al. Restless legs syndrome in Parkinson's disease: clinical characteristics and biochemical correlations. Arq Neuropsiquiatr 2010; 68:869.
  66. Lang AE, Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987; 37:477.
  67. Tan EK, Lum SY, Wong MC. Restless legs syndrome in Parkinson's disease. J Neurol Sci 2002; 196:33.
  68. Gjerstad MD, Tysnes OB, Larsen JP. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 2011; 77:1941.
  69. Arnulf I, Morgan J. Not all that goes "bump in the night" is RLS: leg motor restlessness in PD. Neurology 2011; 77:1936.
  70. Peralta CM, Frauscher B, Seppi K, et al. Restless legs syndrome in Parkinson's disease. Mov Disord 2009; 24:2076.
  71. García-Borreguero D, Allen RP, Benes H, et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007; 22 Suppl 18:S476.
  72. Comella CL, Goetz CG. Akathisia in Parkinson's disease. Mov Disord 1994; 9:545.
  73. Poewe W, Högl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 2004; 63:S12.
  74. Ekbom KA. Restless legs syndrome. Acta Med Scan Suppl 1945; 158:4.
  75. Goodman JD, Brodie C, Ayida GA. Restless leg syndrome in pregnancy. BMJ 1988; 297:1101.
  76. Suzuki K, Ohida T, Sone T, et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep 2003; 26:673.
  77. Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology 2004; 63:1065.
  78. Dzaja A, Wehrle R, Lancel M, Pollmächer T. Elevated estradiol plasma levels in women with restless legs during pregnancy. Sleep 2009; 32:169.
  79. Salih AM, Gray RE, Mills KR, Webley M. A clinical, serological and neurophysiological study of restless legs syndrome in rheumatoid arthritis. Br J Rheumatol 1994; 33:60.
  80. Gudbjörnsson B, Broman JE, Hetta J, Hällgren R. Sleep disturbances in patients with primary Sjögren's syndrome. Br J Rheumatol 1993; 32:1072.
  81. Hassan N, Pineau CA, Clarke AE, et al. Systemic lupus and risk of restless legs syndrome. J Rheumatol 2011; 38:874.
  82. Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996; 312:1339.
  83. Ondo W, Tan EK, Mansoor J. Rheumatologic serologies in secondary restless legs syndrome. Mov Disord 2000; 15:321.
  84. Kanter AH. The effect of sclerotherapy on restless legs syndrome. Dermatol Surg 1995; 21:328.
  85. Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 1994; 23:244.
  86. Chaudhuri KR, Appiah-Kubi LS, Trenkwalder C. Restless legs syndrome. J Neurol Neurosurg Psychiatry 2001; 71:143.
  87. Lutz EG. Restless legs, anxiety and caffeinism. J Clin Psychiatry 1978; 39:693.
  88. LaBan MM, Viola SL, Femminineo AF, Taylor RS. Restless legs syndrome associated with diminished cardiopulmonary compliance and lumbar spinal stenosis--a motor concomitant of "Vesper's curse". Arch Phys Med Rehabil 1990; 71:384.
  89. Markkula J, Lauerma H. Mianserin and restless legs. Int Clin Psychopharmacol 1997; 12:53.
  90. Hattan E, Chalk C, Postuma RB. Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology 2009; 72:955.
  91. Gao X, Schwarzschild MA, Wang H, Ascherio A. Obesity and restless legs syndrome in men and women. Neurology 2009; 72:1255.
  92. Rajabally YA, Shah RS. Restless legs syndrome in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2010; 42:252.
  93. Limousin N, Blasco H, Corcia P, et al. The high frequency of restless legs syndrome in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011; 12:303.
  94. Hornyak M, Feige B, Voderholzer U, et al. Polysomnography findings in patients with restless legs syndrome and in healthy controls: a comparative observational study. Sleep 2007; 30:861.
  95. Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004; 27:560.
  96. Lesage S, Hening WA. The restless legs syndrome and periodic limb movement disorder: a review of management. Semin Neurol 2004; 24:249.
  97. American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, Westchester, IL, American Academy of Sleep Medicine, 2005.
  98. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101.
  99. Chesson A Jr, Hartse K, Anderson WM, et al. Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 2000; 23:237.
  100. Walters AS, Hening W, Rubinstein M, Chokroverty S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep 1991; 14:339.
  101. Dressler D, Thompson PD, Gledhill RF, Marsden CD. The syndrome of painful legs and moving toes. Mov Disord 1994; 9:13.
  102. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004; 79:916.
  103. Earley CJ. Clinical practice. Restless legs syndrome. N Engl J Med 2003; 348:2103.
  104. Nofzinger EA, Fasiczka A, Berman S, Thase ME. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000; 61:858.
  105. Jaber BL, Schiller B, Burkart JM, et al. Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol 2011; 6:1049.
  106. Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011; :CD006009.
  107. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004; 75:92.
  108. Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004; 19:1414.
  109. Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006; 81:17.
  110. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006; 67:1034.
  111. Stiasny K, Möller JC, Oertel WH. Safety of pramipexole in patients with restless legs syndrome. Neurology 2000; 55:1589.
  112. Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68:301.
  113. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003; 26:819.
  114. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004; 5:9.
  115. Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004; 61:1393.
  116. Stiasny K, Röbbecke J, Schüler P, Oertel WH. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial. Sleep 2000; 23:349.
  117. Chaudhuri KR. Restless legs syndrome. N Engl J Med 2003; 349:815.
  118. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004; 63:2272.
  119. Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006; 67:1040.
  120. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006; 67:1225.
  121. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179.
  122. FDA Announces Voluntary Withdrawal of Pergolide Products. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108877.htm.
  123. Scholz H, Trenkwalder C, Kohnen R, et al. Levodopa for restless legs syndrome. Cochrane Database Syst Rev 2011; :CD005504.
  124. Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987; 10:69.
  125. von Scheele C. Levodopa in restless legs. Lancet 1986; 2:426.
  126. Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995; 18:681.
  127. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993; 43:445.
  128. von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990; 47:1223.
  129. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996; 19:205.
  130. Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996; 19:801.
  131. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999; 52:285.
  132. Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996; 100:333.
  133. Montplaisir J, Godbout R, Boghen D, et al. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study. Neurology 1985; 35:130.
  134. Montagna P, Sassoli de Bianchi L, Zucconi M, et al. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984; 69:428.
  135. Read DJ, Feest TG, Nassim MA. Clonazepam: effective treatment for restless legs syndrome in uraemia. Br Med J (Clin Res Ed) 1981; 283:885.
  136. Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009; 72:439.
  137. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009; 32:159.
  138. Happe S, Klösch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001; 57:1717.
  139. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59:1573.
  140. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38:104.
  141. Hening WA, Walters A, Kavey N, et al. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology 1986; 36:1363.
  142. Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16:327.
  143. Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001; 16:1105.
  144. Garcia-Borreguero D, Larrosa O, Williams AM, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010; 74:1897.
  145. Telstad W, Sørensen O, Larsen S, et al. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed) 1984; 288:444.
  146. Wagner ML, Walters AS, Coleman RG, et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996; 19:52.
  147. Derom E, Elinck W, Buylaert W, van der Straeten M. Which beta-blocker for the restless leg? Lancet 1984; 1:857.
  148. Evidente VG, Adler CH, Caviness JN, et al. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000; 15:324.
Topic 4892 Version 17.0

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.